Results 111 to 120 of about 29,286 (231)

Neurocognitive Aging Following Acute Illness: Pathobiology and a Framework for Developing Neurotherapeutic Agents

Brain and Behavior, Volume 16, Issue 6, June 2026.
In this review, we discuss the scientific basis for how neurocognitive aging occurs after critical illness, including sepsis, trauma, and burns, and the clinical need to develop therapies to reduce inflammation, protect the blood–brain barrier, remove senescent cells, and enhance neuroplasticity.
Errin Lawrence, Daniel Fulton, Poppy Brown, Subashini Suresh, Mark Morris, Paraskevi Goggolidou, Sree Chaithanya, Marcus Abbawy, Amelia Wild, Prashant Nasa, Niharika A. Duggal, Fang Gao‐Smith, Zubair Ahmed, Suresh Renukappa, Tonny Veenith   +14 more
wiley   +1 more source

Dasatinib-related Haemorrhagic Optic Neuropathy

, 2018
Dasatinib is a BCR-ABL tyrosine kinase inhibitor (TKI) which also targets platelet-derived growth factor (PDGF). Dasatinib is increasingly used in the treatment of chronic myeloid leukaemia (CML)
Chee Fang Chin
core  

Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT ASC4FIRST (ClinicalTrials.gov NCT04971226) is a pivotal phase 3 clinical trial comparing the efficacy and safety of asciminib vs. standard of care (SoC) tyrosine kinase inhibitors (TKIs) in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML‐CP).
Naoto Takahashi, Dong‐Wook Kim, Inho Kim, Xin Du, Sung‐Eun Lee, Yu Hu, Yoshikane Kikushige, Qian Jiang, Yi Wang, Suning Chen, Huanling Zhu, Tatsunori Goto, Akihiro Tomita, Michiko Ichii, Hirohisa Nakamae, Lei Liu, Beini Liu, Kamel Malek, Tong Zhu, Shengyuan Wu, Jianxiang Wang   +20 more
wiley   +1 more source

Dasatinib in chronic myeloid leukemia: a limited Indian experience

, 2012
Aim: To report our experience of the use of dasatinib in various phases of chronic myeloid leukemia (CML). Methods: Ten patients in various phases of CML, not responding to imatinib and started on dasatinib, were included and analyzed.
Gupta, Ritu, Sharma, Atul, Raina, Vinod, Bahl, Ankur, Kumar, Lalit   +4 more
core   +1 more source

Analysis of Treatment Patterns for Mucosal Melanoma Using Real‐World Data in the SEER‐Medicare–Linked Database

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background Mucosal melanoma (MM) is a rare, aggressive disease, often diagnosed late, and associated with poor survival. Surgical resection is the main potential curative option, but anatomical complexity limits feasibility, and real‐world evidence on treatment patterns remains scarce.
Marjan Zakeri, Samuel Wagner, Xianxin Zhu, Onur Baser   +3 more
wiley   +1 more source

Predictive biomarkers for dasatinib treatment in melanoma

, 2014
Dasatinib has anti-proliferative and anti-invasive effects in melanoma cell lines. However clinical trials have shown modest activity for dasatinib in metastatic melanoma.
O\u27Driscoll, Lorraine
core  

Docetaxel‐Induced Serositis Mimicking Malignant Pleural Effusion

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Pleural effusions are common in patients with cancer. Although their development may signal progressive malignant disease, drug‐induced effusions are a rare and often overlooked cause of exudative pleural effusions. We describe a 50‐year‐old woman with recurrent granulosa cell tumor of the ovary who developed bilateral pleural and pericardial ...
Muhammad Anees, Kevin Chiu, Stephen Goertzen, Carlos A. Jimenez, Saadia A. Faiz   +4 more
wiley   +1 more source

Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background This retrospective series reports outcomes and prognostic factors for advanced chordoma (AC) treatment with molecular targeted therapies (MTTs) in different treatment lines. Methods This is a retrospective series of 57 patients with AC treated between 2004 and 2023 at one of seven participating sarcoma centres.
Astrid Lipplaa, Nadia Hindi, Pawel Teterycz, Robin J. Young, Ioannis Boukonavis, Josefina Cruz, Javier Martinez‐Trufero, Frank Speetjens, Wilco Peul, Robert J. P. van der Wal, Hans Gelderblom   +10 more
wiley   +1 more source

Unveiling Candidate Markers for Drug Resistance or Synthetic Lethality in Cervical Cancer: Integrative Analysis of Genetic and Pharmacoprofiling

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Introduction Systemic cervical cancer management continues to be challenging. Numerous chemotherapies have been approved, but predicting response is difficult due to the lack of biomarkers. Here, we analyze the genetic and protein profiles of 20 cervical cancer cell lines (CCCLs) and explore their correlation with drug response patterns to ...
Suzy Scholl, Elaine Del Nery, Pierre Gestraud, Maral Halladjian, Elodie Girard, Adèle Soria, Elodie Anthony, Leanne De Koning, Nicolas Servant, Els Berns, Maud Kamal   +10 more
wiley   +1 more source

Enhanced PIEZO1 expression in mast cells of mastocytosis skin lesions: Relevance to Darier's sign

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page e598-e601, July 2026.
Yoshiaki Kobayashi, Nobuhiro Nakano, Nguyen Quoc Vuong Tran, Yuki Nakamura, Lisa Minai, Takashi Okamoto, Daiki Nakagomi, Tatsuki R. Kataoka, Tatsuyoshi Kawamura, Atsuhito Nakao   +9 more
wiley   +1 more source